Literature DB >> 20008535

Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy.

I D Jacobsen1, S Brunke, K Seider, T Schwarzmüller, A Firon, C d'Enfért, K Kuchler, B Hube.   

Abstract

Candida glabrata has emerged as an important fungal pathogen of humans, causing life-threatening infections in immunocompromised patients. In contrast, mice do not develop disease upon systemic challenge, even with high infection doses. In this study we show that leukopenia, but not treatment with corticosteroids, leads to fungal burdens that are transiently increased over those in immunocompetent mice. However, even immunocompetent mice were not capable of clearing infections within 4 weeks. Tissue damage and immune responses to microabscesses were mild as monitored by clinical parameters, including blood enzyme levels, histology, myeloperoxidase, and cytokine levels. Furthermore, we investigated the suitability of amino acid auxotrophic C. glabrata strains for in vitro and in vivo studies of fitness and/or virulence. Histidine, leucine, or tryptophan auxotrophy, as well as a combination of these auxotrophies, did not influence in vitro growth in rich medium. The survival of all auxotrophic strains in immunocompetent mice was similar to that of the parental wild-type strain during the first week of infection and was only mildly reduced 4 weeks after infection, suggesting that C. glabrata is capable of utilizing a broad range of host-derived nutrients during infection. These data suggest that C. glabrata histidine, leucine, or tryptophan auxotrophic strains are suitable for the generation of knockout mutants for in vivo studies. Notably, our work indicates that C. glabrata has successfully developed immune evasion strategies enabling it to survive, disseminate, and persist within mammalian hosts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008535      PMCID: PMC2825948          DOI: 10.1128/IAI.01244-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions.

Authors:  Robert P St Onge; Ramamurthy Mani; Julia Oh; Michael Proctor; Eula Fung; Ronald W Davis; Corey Nislow; Frederick P Roth; Guri Giaever
Journal:  Nat Genet       Date:  2007-01-07       Impact factor: 38.330

2.  Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Serena Tomassetti; Daniela Arzeni; Daniele Giannini; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Candida glabrata fungemia: experience in a tertiary care center.

Authors:  Anurag Malani; Jareer Hmoud; Loretta Chiu; Peggy L Carver; Andrew Bielaczyc; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2005-08-24       Impact factor: 9.079

4.  Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.

Authors:  Peter J Smith; Jon A Olson; David Constable; Julie Schwartz; Richard T Proffitt; Jill P Adler-Moore
Journal:  J Antimicrob Chemother       Date:  2007-03-30       Impact factor: 5.790

5.  Cytotoxic and cytokine-inducing properties of Candida glabrata in single and mixed oral infection models.

Authors:  Lulu Li; Helena Kashleva; Anna Dongari-Bagtzoglou
Journal:  Microb Pathog       Date:  2007-01-19       Impact factor: 3.738

6.  Role of granulocyte macrophage colony-stimulating factor in host defense against pulmonary Cryptococcus neoformans infection during murine allergic bronchopulmonary mycosis.

Authors:  Gwo-Hsiao Chen; Michal A Olszewski; Roderick A McDonald; Jason C Wells; Robert Paine; Gary B Huffnagle; Galen B Toews
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

7.  Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis.

Authors:  Gerardo Quezada; Nadezhda V Koshkina; Patrick Zweidler-McKay; Zichao Zhou; Dimitrios P Kontoyiannis; Eugenie S Kleinerman
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

8.  A family of glycosylphosphatidylinositol-linked aspartyl proteases is required for virulence of Candida glabrata.

Authors:  Rupinder Kaur; Biao Ma; Brendan P Cormack
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-24       Impact factor: 11.205

Review 9.  Nosocomial fungal infections: epidemiology, diagnosis, and treatment.

Authors:  Joshua Perlroth; Bryan Choi; Brad Spellberg
Journal:  Med Mycol       Date:  2007-06       Impact factor: 4.076

10.  Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata.

Authors:  Marçal Mariné; Raquel Espada; Juan Torrado; F Javier Pastor; Josep Guarro
Journal:  J Antimicrob Chemother       Date:  2008-02-06       Impact factor: 5.790

View more
  45 in total

Review 1.  Thriving within the host: Candida spp. interactions with phagocytic cells.

Authors:  Pedro Miramón; Lydia Kasper; Bernhard Hube
Journal:  Med Microbiol Immunol       Date:  2013-01-25       Impact factor: 3.402

2.  Functional analysis of selected deletion mutants in Candida glabrata under hypoxia.

Authors:  Payal Gupta; Ramesh Chand Meena; Navin Kumar
Journal:  3 Biotech       Date:  2017-06-29       Impact factor: 2.406

3.  Usefulness of the Non-conventional Caenorhabditis elegans Model to Assess Candida Virulence.

Authors:  Marcelo Ortega-Riveros; Iker De-la-Pinta; Cristina Marcos-Arias; Guillermo Ezpeleta; Guillermo Quindós; Elena Eraso
Journal:  Mycopathologia       Date:  2017-05-18       Impact factor: 2.574

4.  Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses.

Authors:  Shaoji Cheng; Cornelius J Clancy; Douglas J Hartman; Binghua Hao; M Hong Nguyen
Journal:  Infect Immun       Date:  2014-05-05       Impact factor: 3.441

5.  Effects of immune suppression in murine models of disseminated Candida glabrata and Candida tropicalis infection and utility of a synthetic peptide vaccine.

Authors:  Hong Xin
Journal:  Med Mycol       Date:  2019-08-01       Impact factor: 4.076

6.  Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells.

Authors:  Luís Vale-Silva; Françoise Ischer; Salomé Leibundgut-Landmann; Dominique Sanglard
Journal:  Infect Immun       Date:  2013-03-04       Impact factor: 3.441

7.  Investigation of the function of Candida albicans Als3 by heterologous expression in Candida glabrata.

Authors:  Yue Fu; Quynh T Phan; Guanpingsheng Luo; Norma V Solis; Yaoping Liu; Brendan P Cormack; John E Edwards; Ashraf S Ibrahim; Scott G Filler
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

Review 8.  The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida.

Authors:  Russell E Lewis; Pierluigi Viale; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2012-06-22       Impact factor: 5.882

9.  Immune evasion, stress resistance, and efficient nutrient acquisition are crucial for intracellular survival of Candida glabrata within macrophages.

Authors:  Katja Seider; Franziska Gerwien; Lydia Kasper; Stefanie Allert; Sascha Brunke; Nadja Jablonowski; Tobias Schwarzmüller; Dagmar Barz; Steffen Rupp; Karl Kuchler; Bernhard Hube
Journal:  Eukaryot Cell       Date:  2013-12-20

Review 10.  Two unlike cousins: Candida albicans and C. glabrata infection strategies.

Authors:  Sascha Brunke; Bernhard Hube
Journal:  Cell Microbiol       Date:  2013-01-14       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.